The following is from Gerald's mid year report released about a month ago. I expect we'll get an update in tomorrow's R&R presentation.
We are evaluating a variety of financing options including joint ventures, licensing, debt, equity and grant funding to give the Company sufficient capital to operate over the foreseeable future as our products reach major milestones.
Over the next year, we expect to make significant progress in the following areas:
1) Advancing LymPro through to commercialization sales as an LDT via CLIA;
2) Conducting IND-enabling studies for MANF in the non-human primate model of Parkinson's disease;
3) Completing proof-of-concept studies and preparing to file an IND for MANF in at least one orphan indication;
4) Completing feasibility studies for MANF in diabetes, ischemic heart disease and traumatic brain injury.
We are hopeful to meet a number of other important milestones in our NuroPro and PhenoGuard programs while continuing to evaluate new business opportunities rooted in our deep understanding of the central nervous system. If we achieve these objectives, both our therapeutics and diagnostics subsidiaries will be well positioned to thrive, and in turn the Company will be focused on evaluating ways to capture that value.